Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Current Liabilities: 2011-2025

Historic Total Current Liabilities for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $56.5 million.

  • Adma Biologics' Total Current Liabilities rose 25.81% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 25.81%. This contributed to the annual value of $55.5 million for FY2024, which is 11.52% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Total Current Liabilities is $56.5 million, which was down 24.62% from $74.9 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Total Current Liabilities registered a high of $74.9 million during Q2 2025, and its lowest value of $18.2 million during Q2 2021.
  • Over the past 3 years, Adma Biologics' median Total Current Liabilities value was $49.8 million (recorded in 2023), while the average stood at $50.3 million.
  • In the last 5 years, Adma Biologics' Total Current Liabilities surged by 96.30% in 2021 and then fell by 5.85% in 2023.
  • Quarterly analysis of 5 years shows Adma Biologics' Total Current Liabilities stood at $30.4 million in 2021, then climbed by 29.26% to $39.3 million in 2022, then climbed by 26.84% to $49.8 million in 2023, then increased by 11.52% to $55.5 million in 2024, then increased by 25.81% to $56.5 million in 2025.
  • Its last three reported values are $56.5 million in Q3 2025, $74.9 million for Q2 2025, and $53.5 million during Q1 2025.